IN THIS MONTH'S ISSUE

• “Surprise Medical Bills” May Displace Rx Drugs As Healthcare Focus In 2020

  The same politics that fuel patient ire at the drug industry for rising out-of-pocket costs manifest in the other major focus of health legislation this year: “surprise medical bills,” which occur when a patient receives care from an out-of-network healthcare provider.

• How S.O.F.T. Skills Can Help Close The Talent Gap

  New research suggests biopharma companies urgently need to accelerate development of S.O.F.T. skills in order to decrease the talent gap that threatens the industry’s success in providing innovative therapies for patients in need.

• Insights From A First-Time Biotech CEO

  Alessandro Riva, M.D. is a first-time biotech CEO who shares some of the values and leadership strategies he has learned over the years, including how to foster a culture of relentless innovation.

• The Global Regulatory And Quality Environment For Biopharma Outsourcing

  It is critical that organizations looking to engage an external contract service provider be aware of new regulations to align their programs with the latest expectations for each relevant market.

• Making Progress On A Micro-Budget

  Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.